Free Trial
NASDAQ:ORMP

Oramed Pharmaceuticals 5/15/2025 Earnings Report

Oramed Pharmaceuticals logo
$2.28 +0.02 (+0.88%)
Closing price 06/4/2025 04:00 PM Eastern
Extended Trading
$2.27 -0.01 (-0.44%)
As of 08:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oramed Pharmaceuticals EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.03
Beat/Miss
Missed by -$0.16
One Year Ago EPS
N/A

Oramed Pharmaceuticals Revenue Results

Actual Revenue
$2.00 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oramed Pharmaceuticals Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Oramed Pharmaceuticals' next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

Oramed Pharmaceuticals Earnings Headlines

Oramed Pharm Extends Stock Buyback Program
Dalio heeds Buffett’s warning… [$319 million stake in gold]
Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profitable miners selling at deep discounts. I call this price gap the Golden Anomaly — and I’ve put together a full report on my top four picks.
See More Oramed Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oramed Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oramed Pharmaceuticals and other key companies, straight to your email.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals (NASDAQ:ORMP) engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

View Oramed Pharmaceuticals Profile

More Earnings Resources from MarketBeat